Seminars in Cancer Biology, Journal Year: 2024, Volume and Issue: 106-107, P. 179 - 191
Published: Oct. 22, 2024
Language: Английский
Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161993 - 161993
Published: March 1, 2025
Language: Английский
Citations
0
ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown
Published: April 15, 2025
Recently, metal-organic frameworks (MOFs) have emerged as promising platforms to fabricate photothermal therapeutic materials cure tumors, but the toxic heavy metals in many MOFs may pose great threats normal cells. In consideration of low toxicity bismuth, herein we made efforts synthesize porous bismuth-based (Bi-MOFs) construct conversion for cancer treatment. By reaction 4,4',4''-tricarboxylic triphenylamine (H3TCA) and Bi(NO3)3 under solvothermal conditions, a Bi-MOF was obtained with formula {[Bi2(TCA)2(H2O)3]·6DMF·21H2O}n (Bi-TCA). Structural analysis revealed that complex Bi-TCA displayed three-dimensional (3D) coordination framework featuring abundant accessible channels cages porosity 73.3% according calculating results PLATON. Due high porosity, could effectively encapsulate dye crystal violet (CV) into voids resulting dye-loaded composite CV@Bi-TCA exhibited extended red-shifted light-absorbing property enhanced capability 455 nm laser irradiation. Further anticancer experiments demonstrated efficiently inhibit growth breast cells both vitro vivo This work promote investigations on low-toxicity Bi-MOFs therapy.
Language: Английский
Citations
0
Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)
Published: May 17, 2025
Leukemia, a group of blood cancers, presents significant global health challenge. Despite advancements in conventional therapies like chemotherapy and immunotherapy, the need for more effective less toxic treatments remains. Nanotechnology offers promising avenue targeted drug delivery immune modulation fight against leukemia. Through utilization nanomaterials' special qualities, their small size, large surface area, capacity to transport variety payloads, scientists are creating novel ways get around drawbacks treatments. These strategies include delivery, cell activation, overcoming resistance. However, challenges remain translating these nanotechnological approaches into clinical applications. Addressing issues such as toxicity, biodistribution, regulatory hurdles is crucial successful development nanomedicine In conclusion, nanotechnology future treatment Continued research essential unlock full potential nanomaterials improve patient outcomes. The nanotechnology-based effectiveness leukemia explored this review. We go over function different delivering therapeutic agents cells, liposomes, polymeric nanoparticles, inorganic anoparticles. also investigate engineering influence system promote anti-tumor reactions.
Language: Английский
Citations
0
World Journal of Gastrointestinal Oncology, Journal Year: 2024, Volume and Issue: 16(4), P. 1134 - 1153
Published: April 9, 2024
Pancreatic cancer (PC) is characterized by its extremely aggressive nature and ranks 14th in the number of new cases worldwide. However, due to complexity, it 7th list most lethal cancers The pathogenesis PC involves several complex processes, including familial genetic factors associated with risk such as obesity, diabetes mellitus, chronic pancreatitis, smoking. Mutations genes KRAS, TP53 , SMAD4 are linked appearance malignant cells that generate pancreatic lesions and, consequently, cancer. In this context, some therapies used for PC, one which immunotherapy, promising various other types but has shown little response treatment resistance mechanisms contribute a drop immunotherapy efficiency. It therefore clear tumor microenvironment (TME) huge impact on process, since cellular non-cellular elements create an immunosuppressive environment, dense desmoplastic stroma cancer-associated fibroblasts, stellate cells, extracellular matrix, cells. Linked mutations act T resulting shortage CD8+ limited expression activation markers interferon-gamma. way, finding strategies make possible manipulate necessary. Thus, techniques use TME modulators block receptors stromal molecules resistance, manipulation specific regions, microRNAs, modulation extrinsic intrinsic above all, therapeutic models combine these constitute future therapy. study aims elucidate main ways manipulating more efficient therapy patients reduction lethality
Language: Английский
Citations
2
Molecular Aspects of Medicine, Journal Year: 2024, Volume and Issue: 100, P. 101318 - 101318
Published: Sept. 10, 2024
Language: Английский
Citations
2
Published: April 28, 2024
Triple-negative breast cancer (TNBC), lacking specific receptors found in other subtypes, poses significant treatment challenges due to limited therapeutic options. Therefore, it is necessary develop novel approaches for TNBC. In the last few decades, many attempts have been reported alternative tools TNBC treatment: immunotherapy, radiotherapy, targeted therapy, combination and nanotechnology-based therapy. Among them, therapy show most promise treatment. This review outlines recent advancements these areas, highlighting efficacy of (immunotherapy paired with chemotherapy, or radiotherapy) both preclinical clinical stages therapies utilizing various nanoparticles loaded anticancer agents, nucleic acids, immunotherapeutics, CRISPRs
Language: Английский
Citations
2
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: June 6, 2024
Background It has been reported that tumor immune microenvironment performs a vital role in progress. However, acting mechanism of cell related genes (IRGs) esophageal squamous carcinoma (ESCC) is uncertain. Methods TCGA-ESCC, GSE23400, GSE26886, GSE75241, and GSE196756 datasets were gained via public databases. First, differentially expressed (DEGs) between ESCC control samples from GSE75241 screened out by differential expression analysis, overlapping DEGs identified. Single-cell transcriptome data applied to explore cells might be involved regulation ESCC. Then, weighted gene co-expression network analysis was screen IRGs. Next, IRGs (DE-IRGs) identified DEGs, incorporated into univariate Cox, least absolute shrinkage selection operator, multivariate Cox acquire prognosis-related genes, grouped high-/low-risk groups on the basis median risk score. Finally, prognosis model immunotherapy analyzed. Results Totally 248 yielded 3,915 459 1,641 GSE75241. found B cells, dendritic monocytes, neutrophils, natural killer T development. Besides, MEred, MEblack, MEpink, MEblue MEbrown modules considered as key because their highest correlations with subtypes. A total 154 DE-IRGs taking intersection modules. Moreover, CTSC, ALOX12, RMND5B Obviously, Exclusion TIDE scores notably lower high-risk group than other one, indicating more responsive immunotherapy. Conclusions Through bioinformatic we consisting (CTSC, RMND5B) ESCC, providing new ideas for studies treatment
Language: Английский
Citations
1
Biotechnology and Applied Biochemistry, Journal Year: 2024, Volume and Issue: 71(6), P. 1226 - 1234
Published: June 22, 2024
Abstract In this study, we aimed to develop nanobodies targeting receptor tyrosine kinase‐like orphan 1 (ROR1) for cancer diagnosis and therapy. We immunized alpacas with ROR1, extracted RNA from their blood, converted it complementary DNA (cDNA) amplify the VHH (variable domain of heavy‐chain antibodies) sequence. This sequence was used construct a phage library capacity 8 ×10 . Screening identified high‐affinity nanobody, HCAbs1, which binds effectively ROR1. ELISA surface plasmon resonance analyses revealed HCAbs1's binding affinities ROR1 at 4.42 12.9 nM, respectively. Functional tests showed HCAbs1 could reduce extracellular signal‐regulated kinase (ERK) phosphorylation levels induced by Wnt5a in ROR1‐transfected cells. Our findings highlight potential diagnosing treating cancers through
Language: Английский
Citations
1
Biomedical Materials, Journal Year: 2024, Volume and Issue: 19(6), P. 065015 - 065015
Published: Sept. 23, 2024
Abstract Gene therapy often fails due to enzyme degradation and low transfection efficiency, single gene usually cannot completely kill tumor cells. Several studies have reported that tripartite motif-containing protein 37 (TRIM37) plays a significant role in promoting the occurrence development of triple negative breast cancer (TNBC). Herein, we constructed siTRIM37 IR780 co-loaded nanobubbles (NBs) achieve combination sonodynamic (SDT) against TNBC. On one hand, ultrasound irradiation causes siRNA@IR780 NBs rupture produce targeted NB destruction effect, which promotes entry into cells, increasing local concentration efficiency. other under stimulation ultrasound, generates reactive oxygen species TNBC Mechanism reveal TRIM37 is an anti-apoptotic TNBC, inhibiting expression can induce cell death through apoptotic pathway. And SDT aggravate degree apoptosis increase death. Therefore, NBs-mediated may provide new treatment approach for future.
Language: Английский
Citations
1
Seminars in Cancer Biology, Journal Year: 2024, Volume and Issue: 106-107, P. 179 - 191
Published: Oct. 22, 2024
Language: Английский
Citations
1